← Back to Search

JAK Inhibitor

Ruxolitinib + Chemotherapy for Leukemia

Phase 2
Waitlist Available
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Completed a 4-drug Induction therapy regimen and had end-Induction minimal residual disease (MRD) assessed
Participant is 2 years to 21 years in Canada
Must not have
Calculated creatinine clearance or radioisotope glomerular filtration rate < 70 mL/min/1.73 m^2
Trisomy 21 (Down syndrome)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new cancer drug, ruxolitinib, in combination with standard chemotherapy to treat B-cell acute lymphoblastic leukemia. The study will first find the best dose of ruxolitinib to use with chemotherapy, then test how well the combination works at that dose.

Who is the study for?
This trial is for children and young adults aged 1 to 21 with high-risk B-cell acute lymphoblastic leukemia that shows a specific genetic profile. Participants must have completed initial chemotherapy, not be pregnant or fathering a child, and cannot have certain other health conditions like Down syndrome or active hepatitis.
What is being tested?
The study tests Ruxolitinib combined with standard chemotherapy in two parts: first finding the best dose of Ruxolitinib, then checking how well it works at that dose. It's for kids who've just been diagnosed and haven't had much treatment yet.
What are the potential side effects?
Possible side effects include liver issues, infections due to low white blood cell counts, allergic reactions to medication components, nausea from chemo drugs, and potential increased bleeding risk due to low platelets.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I finished a 4-drug treatment and had a test for remaining cancer cells.
Select...
I am between 2 and 21 years old and live in Canada.
Select...
I was diagnosed between the ages of 1 and 21.
Select...
My leukemia is high-risk and was identified as Ph-like at diagnosis.
Select...
My cancer has been analyzed for specific gene changes.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My kidney function, measured by creatinine clearance, is below 70 mL/min.
Select...
I have Down syndrome.
Select...
My leukemia is BCR-ABL1 positive.
Select...
I am HIV positive.
Select...
My liver enzyme (ALT) levels are five times higher than normal.
Select...
I have only received hydroxyurea or steroids before my main cancer treatment.
Select...
I have been diagnosed with cirrhosis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2020 Phase 3 trial • 149 Patients • NCT02038036
33%
Anaemia
19%
Hypertension
17%
Nasopharyngitis
16%
Weight increased
14%
Herpes zoster
14%
Constipation
14%
Abdominal pain
14%
Headache
12%
Pruritus
12%
Back pain
12%
Epistaxis
12%
Pyrexia
12%
Dizziness
10%
Asthenia
10%
Fatigue
10%
Cough
10%
Oedema peripheral
10%
Arthralgia
9%
Thrombocytosis
9%
Upper respiratory tract infection
9%
Hypercholesterolaemia
7%
Haematoma
7%
Dyslipidaemia
7%
Pain in extremity
7%
Abdominal discomfort
7%
Diarrhoea
7%
Dyspepsia
7%
Vomiting
7%
Blood lactate dehydrogenase increased
7%
Memory impairment
7%
Dyspnoea
5%
Tinnitus
5%
Osteoarthritis
5%
Leukocytosis
5%
Thrombocytopenia
5%
Flatulence
5%
Nausea
5%
Sinusitis
5%
Basal cell carcinoma
5%
Neuropathy peripheral
5%
Hyperuricaemia
3%
Paraesthesia
3%
Bronchitis
3%
Cystitis
3%
Blood creatine phosphokinase increased
3%
Skin ulcer
3%
Abdominal pain upper
3%
Pulmonary embolism
3%
Pneumonia
3%
Influenza
3%
Myalgia
3%
Urinary tract infection
3%
Depression
2%
Peripheral artery thrombosis
2%
Vertigo
2%
Acute pulmonary oedema
2%
Night sweats
2%
Intervertebral disc protrusion
2%
Urethral stenosis
2%
Ureterolithiasis
2%
Localised infection
2%
Pericardial effusion
2%
Acute myocardial infarction
2%
Syncope
2%
Gastrooesophageal reflux disease
2%
General physical health deterioration
2%
Atrial fibrillation
2%
Cardiac disorder
2%
Mitral valve incompetence
2%
Vertigo positional
2%
Retinal artery occlusion
2%
Visual acuity reduced
2%
Gastrointestinal haemorrhage
2%
Oesophageal varices haemorrhage
2%
Lower respiratory tract infection
2%
Pyelonephritis
2%
Respiratory tract infection
2%
Sepsis
2%
Tendon rupture
2%
Ulna fracture
2%
Weight decreased
2%
Decreased appetite
2%
Hyponatraemia
2%
Blast cell crisis
2%
Bone marrow tumour cell infiltration
2%
Lung adenocarcinoma
2%
Metastases to spine
2%
Myelofibrosis
2%
Prostatic adenoma
2%
Squamous cell carcinoma of skin
2%
Nephrolithiasis
2%
Gamma-glutamyltransferase increased
2%
Haematocrit increased
2%
Musculoskeletal pain
2%
Ischaemic stroke
2%
Diabetes mellitus
100%
80%
60%
40%
20%
0%
Study treatment Arm
All Crossover Patients
Best Available Therapy
Ruxolitinib

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Ruxolitinib in combination with chemotherapyExperimental Treatment13 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Leucovorin Calcium
2011
Completed Phase 3
~12500
Methotrexate
2019
Completed Phase 4
~4400
Pegaspargase
2010
Completed Phase 3
~10000
Vincristine Sulfate
2005
Completed Phase 3
~10270
Thioguanine
2012
Completed Phase 4
~11580
Mercaptopurine
2012
Completed Phase 4
~13290
Prednisone
2014
Completed Phase 4
~2500
Ruxolitinib
2018
Completed Phase 3
~1170
Cyclophosphamide
2010
Completed Phase 4
~2310
Cytarabine
2016
Completed Phase 3
~3330
Dexamethasone
2007
Completed Phase 4
~2650
Doxorubicin
2012
Completed Phase 3
~8030

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
393 Previous Clinical Trials
63,795 Total Patients Enrolled
20 Trials studying Leukemia
1,445 Patients Enrolled for Leukemia
Children's Oncology GroupNETWORK
460 Previous Clinical Trials
239,827 Total Patients Enrolled
172 Trials studying Leukemia
103,096 Patients Enrolled for Leukemia
Sarah Tasian, MDStudy ChairChildren's Hospital of Philadelphia, Philadelphia, PA
1 Previous Clinical Trials
10 Total Patients Enrolled
1 Trials studying Leukemia
10 Patients Enrolled for Leukemia
Mignon Loh, MDStudy ChairUCSF Benioff Children's Hospital, San Francisco, CA
5 Previous Clinical Trials
12,270 Total Patients Enrolled
4 Trials studying Leukemia
12,263 Patients Enrolled for Leukemia
Albert Assad, MDStudy DirectorIncyte Corporation
5 Previous Clinical Trials
486 Total Patients Enrolled

Media Library

Ruxolitinib (JAK Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT02723994 — Phase 2
Leukemia Research Study Groups: Ruxolitinib in combination with chemotherapy
Leukemia Clinical Trial 2023: Ruxolitinib Highlights & Side Effects. Trial Name: NCT02723994 — Phase 2
Ruxolitinib (JAK Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02723994 — Phase 2
~20 spots leftby Feb 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top